Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOWL Werewolf Therapeutics	$1.41 +0.7%	$1.19	$0.60 ▼ $4.18	$62.82M	0.62	442,589 shs	402,513 shs
MREO Mereo BioPharma Group	$1.77 -0.6%	$2.46	$1.57 ▼ $5.02	$283.02M	0.46	1.35 million shs	2.37 million shs
OVID Ovid Therapeutics	$0.55 +14.8%	$0.33	$0.24 ▼ $1.47	$34.08M	0.13	558,318 shs	3.44 million shs
VRCA Verrica Pharmaceuticals	$0.82 -4.5%	$0.64	$0.38 ▼ $8.01	$79.10M	1.76	631,598 shs	345,421 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOWL Werewolf Therapeutics	+0.71%	+18.49%	+13.71%	+53.43%	-51.04%
MREO Mereo BioPharma Group	-0.56%	+9.94%	-38.33%	-23.04%	-54.50%
OVID Ovid Therapeutics	+14.75%	+35.80%	+85.87%	+90.58%	-46.08%
VRCA Verrica Pharmaceuticals	-4.55%	+1.20%	+41.03%	+66.42%	-89.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HOWL Werewolf Therapeutics	3.5061 of 5 stars	3.5	5.0	0.0	0.0	5.0	0.6
MREO Mereo BioPharma Group	1.5881 of 5 stars	3.6	1.0	0.0	1.5	1.7	0.0
OVID Ovid Therapeutics	4.6781 of 5 stars	3.6	5.0	4.6	2.4	2.5	0.6
VRCA Verrica Pharmaceuticals	4.3878 of 5 stars	3.1	5.0	4.7	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOWL Werewolf Therapeutics	3.00	Buy	$8.33	491.02% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.20	306.78% Upside
OVID Ovid Therapeutics	3.20	Buy	$3.13	468.18% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$8.00	880.03% Upside

Current Analyst Ratings Breakdown

Latest VRCA, MREO, OVID, and HOWL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/14/2025	VRCA Verrica Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/9/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $6.00
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOWL Werewolf Therapeutics	$1.88M	33.65	N/A	N/A	$1.65 per share	0.85
MREO Mereo BioPharma Group	$10M	28.14	N/A	N/A	$0.39 per share	4.54
OVID Ovid Therapeutics	$570K	68.61	N/A	N/A	$0.96 per share	0.57
VRCA Verrica Pharmaceuticals	$7.57M	9.97	N/A	N/A	($0.11) per share	-7.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOWL Werewolf Therapeutics	-$70.51M	-$1.67	N/A	N/A	N/A	N/A	-89.37%	-54.87%	8/14/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$76.58M	-$1.20	N/A	N/A	N/A	N/A	N/A	-145.63%	8/13/2025 (Estimated)

Latest VRCA, MREO, OVID, and HOWL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HOWL Werewolf Therapeutics	-$0.50	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	VRCA Verrica Pharmaceuticals	-$0.10	N/A	N/A	N/A	$4.37 million	N/A
8/12/2025	Q2 2025	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	N/A	N/A	N/A	$0.09 million	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
5/13/2025	Q1 2025	VRCA Verrica Pharmaceuticals	-$0.14	-$0.10	+$0.04	-$0.10	$2.53 million	$3.44 million
5/8/2025	Q1 2025	HOWL Werewolf Therapeutics	-$0.44	-$0.40	+$0.04	-$0.40	$0.30 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOWL Werewolf Therapeutics	0.46	8.09	8.09
MREO Mereo BioPharma Group	N/A	8.92	8.92
OVID Ovid Therapeutics	0.22	4.93	4.93
VRCA Verrica Pharmaceuticals	N/A	1.34	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOWL Werewolf Therapeutics	64.84%
MREO Mereo BioPharma Group	62.83%
OVID Ovid Therapeutics	72.24%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
HOWL Werewolf Therapeutics	23.60%
MREO Mereo BioPharma Group	5.50%
OVID Ovid Therapeutics	13.10%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOWL Werewolf Therapeutics	40	44.87 million	34.28 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
VRCA Verrica Pharmaceuticals	40	92.49 million	42.55 million	Optionable

VRCA, MREO, OVID, and HOWL Headlines

Recent News About These Companies

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of "Hold" by Analysts

July 16 at 3:57 AM | americanbankingnews.com

Verrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...

July 12, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc News (VRCA) - Investing.com

July 11, 2025 | investing.com

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed ...

July 11, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts

July 11, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Down 4.9% - Should You Sell?

July 10, 2025 | marketbeat.com

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

July 9, 2025 | globenewswire.com

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

July 1, 2025 | globenewswire.com

Verrica Shareholder Sues Board Over FDA Approval Hurdle Claims

June 27, 2025 | news.bloomberglaw.comN

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025 | globenewswire.com

Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline

May 18, 2025 | msn.com

Verrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference Call

May 13, 2025 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025 | globenewswire.com

6VRCA : Earnings Outlook For Verrica Pharmaceuticals

May 13, 2025 | benzinga.com

Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update

May 11, 2025 | msn.com

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025 | globenewswire.com

Verrica Pharmaceuticals CEO to Present at Citizens Life Sciences Conference

May 4, 2025 | msn.com

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30, 2025 | globenewswire.com

Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%

April 9, 2025 | aaii.comA

Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH

April 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

The Meteoric Rise of Rocket Lab: A Space Stock to Watch
By Ryan Hasson | July 11, 2025
View The Meteoric Rise of Rocket Lab: A Space Stock to Watch
SoundHound Rises as Short Sellers Exit and AI Demand Grows
By Thomas Hughes | July 9, 2025
View SoundHound Rises as Short Sellers Exit and AI Demand Grows
The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
By Jeffrey Neal Johnson | June 22, 2025
View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
Tesla: 2 Plays Ahead of Next Week's Earnings Report
By Sam Quirke | July 15, 2025
View Tesla: 2 Plays Ahead of Next Week's Earnings Report
AI Infrastructure Is Exploding—Don’t Overlook CoreWeave & Nebius
By Jeffrey Neal Johnson | July 17, 2025
View AI Infrastructure Is Exploding—Don’t Overlook CoreWeave & Nebius

VRCA, MREO, OVID, and HOWL Company Descriptions

Werewolf Therapeutics NASDAQ:HOWL

$1.41 +0.01 (+0.71%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.40 0.00 (-0.35%)

As of 07/18/2025 06:53 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Mereo BioPharma Group NASDAQ:MREO

$1.77 -0.01 (-0.56%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.75 -0.02 (-1.13%)

As of 07/18/2025 07:57 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Ovid Therapeutics NASDAQ:OVID

$0.55 +0.07 (+14.75%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.56 +0.01 (+1.09%)

As of 07/18/2025 07:58 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Verrica Pharmaceuticals NASDAQ:VRCA

$0.82 -0.04 (-4.55%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.81 -0.01 (-0.77%)

As of 07/18/2025 06:38 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time